ApoCell to Conduct Studies in Support of Novel Pfizer Cancer Drug Trial
A new paradigm in clinical trial design
Selecting patients for clinical trials based on predicting drug response can help bring cancer drugs to market sooner. Many new cancer drugs target specific parts of cancer cells or related biochemical processes. Although they are very powerful and much better tolerated, scientists have found that individual response to these agents can vary widely. A diagnostic test that indicates whether a patient will respond to treatment is very promising.
Diagnostic biomarkers - transforming biology into information
Cancer biomarkers are the biological "neon signs" that advertise the presence or absence of cancer cells. A very complex disorder, cancer manifests itself in many ways. Cancer biomarkers must therefore distinguish and detect the presence or future presence of a specific malignancy with a high degree of accuracy.
Dr. Darren Davis, ApoCell's CEO, comments, "We have isolated and measured cancer biomarker intensity for ten years using advanced technologies such as lasers. We can detect and measure very small changes in protein expression and have shown that protein biomarker expression correlates with clinical outcome and can be used to predict the efficacy of cancer drug therapies. We are very excited to work with Pfizer on this project."
About ApoCell Inc.
ApoCell Inc. was founded in 2004 to commercialize biomarker technologies that were developed at the University of Texas M.D. Anderson Cancer Center. This proprietary method monitors the effectiveness of cancer drugs by measuring biomarker expression patterns in tumor cells. The company has conducted 38 clinical studies with over 11,000 specimens on 28 investigational drugs and eight FDA-approved cancer drugs.
ApoCell Inc., Houston
Darren Davis, 713-440-6070
Posted: January 2008